Balis, Frank M.
Thompson, Patrick A.
Mosse, Yael P.
Blaney, Susan M.
Minard, Charles G.
Weigel, Brenda J.
Fox, Elizabeth
Clinical trials referenced in this document:
Documents that mention this clinical trial
First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium
https://doi.org/10.1007/s00280-016-3220-6
Funding for this research was provided by:
Pfizer
Children's Oncology Group
National Cancer Institute (UM1 CA097452)
Cookies for Kid's Cancer Foundation
Article History
Received: 2 December 2016
Accepted: 8 December 2016
First Online: 28 December 2016
Compliance with ethical standards
:
: F. Balis has research funding from United Therapeutics Corp.; Y. Mosse has research funding from Pfizer, Inc. and Novartis; E. Fox has research funding from Glaxo Smith Kline, Merck and Incyta.
: The phase 1 clinical trial of crizotinib was reviewed and approved by the Institutional Review Boards at each participating institution, and the clinical trial was conducted in accordance with the ethical standards outlined in the Declaration of Helsinki and the US Federal Regulations governing research in human subjects.